Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.07M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
Market Cap
$7.12M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.15M
Net Profit Margin
-1977.59%
TTM Avg
-1280.67%
3Y Avg
-1780.71%
5Y Avg
-1415.68%
Market Cap
$7.19M
Net Profit Margin
-6523.04%
TTM Avg
-4247.49%
3Y Avg
-2263.82%
5Y Avg
-1493.48%
Market Cap
$7.19M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.88M
Net Profit Margin
0.00%
TTM Avg
-970.10%
3Y Avg
-487.29%
5Y Avg
1862.33%
Market Cap
$7.31M
Net Profit Margin
-0.61%
TTM Avg
-82.77%
3Y Avg
-131.16%
5Y Avg
-372.00%
Market Cap
$6.74M
Net Profit Margin
-611.47%
TTM Avg
-627.26%
3Y Avg
-917.71%
5Y Avg
-6297.45%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.07M | 0.00% | 0.00% | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.04M | 0.00% | 0.00% | -287.91% | -676.70% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | 0.00% | 0.00% | 0.00% | 0.00% |
| Longeveron Inc. (LGVN)vs › | $7.15M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.19M | -6523.04% | -4247.49% | -2263.82% | -1493.48% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Exicure, Inc. (XCUR)vs › | $6.88M | 0.00% | -970.10% | -487.29% | 1862.33% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.61% | -82.77% | -131.16% | -372.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | -611.47% | -627.26% | -917.71% | -6297.45% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
